# Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies

## TL;DR

This paper discusses how inherited genetic mutations, not acquired ones, can cause myeloid blood cancers like AML and MDS, and highlights the importance of identifying these mutations for better treatment and family care.

## Contribution

The paper emphasizes the clinical and diagnostic importance of germline mutations in myeloid malignancies, offering insights into treatment and genetic counseling.

## Key findings

- Germline mutations in genes like RUNX1, GATA2, and DDX41 significantly increase the risk of myeloid malignancies.
- Identifying germline mutations is crucial for treatment decisions, especially for stem cell transplants and genetic counseling.
- Non-hematopoietic germline DNA testing is essential for accurate diagnosis and personalized care.

## Abstract

Myeloid neoplasms with germline predisposition develop blood cancers, such as AML and MDS, and arise from inherited genetic mutations rather than acquired ones. Individuals born with errors in genes like RUNX1, GATA2, or DDX41 have a significantly increased lifetime risk of developing hematologic malignancies. Identifying hereditary etiology is vital as it influences treatment strategies, including donor selection for stem cell transplant, and necessitates genetic counseling and surveillance for at-risk family members.

Myeloid neoplasms (MNs) with germline predisposition represent a distinct, increasingly recognized category in the WHO classification, encompassing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) arising in the context of an inherited genetic alteration or mutation. While often presenting at a younger age or with characteristic cytopenias with or without organ dysfunction, some can manifest in adulthood, highlighting the need for vigilance regardless of age or family history. Key predisposing genes include transcription factors (e.g., RUNX1, CEBPA) and genes involved in RNA splicing and telomere biology disorders. Identification of these germline mutations is critical as MNs with germline predisposition dictate specific therapeutic strategies—particularly for hematopoietic stem cell transplantation (HSCT)—and require genetic counseling and surveillance for at-risk relatives. Accurate diagnosis often requires non-hematopoietic germline DNA testing, which provides important biological insights into the development of different myeloid neoplasms and directs personalized patient care.